Ivetta Danylesko
- 5 Doskonałe • 2 opinie
- 23 lat doświadczenia
- 3000+ procedury na koncie
- Izrael, Ramat Gan, Centrum Medyczne Sheba
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.
Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.
He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.
He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).
Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.
She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.
Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.
Kierowniczka Oddziału Hematologii w Centrum Medycznym Hadassah – profesor Ben-yehuda była pionierką terapii genowej i przeszczepów szpiku kostnego w leczeniu chłoniaków.
Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.
She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.
Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.
Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.
He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.
Prof. dr Serdar Bedii Omay opublikował ponad 65 artykułów naukowych z zakresu hematologii i przeszczepiania szpiku kostnego, a także odbył szerokie szkolenie w Japonii.
Dr Apak specjalizuje się w chemioterapii chłoniaków dziecięcych z ponad 30-letnim doświadczeniem. Kieruje Oddziałem Hematologii i Onkologii Dziecięcej na Uniwersytecie Stambulskim-Cerrahpaşa.
Prof. dr Rafet Eren jest profesorem nadzwyczajnym w dziedzinie hematologii, autorem ponad 50 publikacji i laureatem nagród badawczych w dziedzinie chłoniaków i onkologii hematologicznej.
Dr Omer Dogru specjalizuje się w hematologii i onkologii dziecięcej, posiadając szerokie przeszkolenie w zakresie chemioterapii chłoniaków oraz przeszczepiania szpiku kostnego.
Specjalizuje się w leczeniu chłoniaków, posiada ponad 13 lat doświadczenia w hematologii. Obecnie praktykuje w Liv Hospital Ulus.
Prof. Baytan specjalizuje się w nowotworach dziecięcych, w tym w chłoniaku, posiadając ponad 20 lat doświadczenia w hematologii dziecięcej.
Dr Shaunak Valame specjalizuje się w chemioterapii chłoniaków, posiadając wiedzę w zakresie terapii celowanych i molekularnych badań nad rakiem. Przedstawił przełomowe badania nad rakiem żołądka na sympozjum ASCO Gastrointestinal Cancer Symposium.
Kieruje Oddziałem Hematologii i Onkologii Dziecięcej w HM Hospitales – czołowy ekspert w leczeniu chłoniaków dziecięcych, z ponad 30-letnim doświadczeniem.
Ponad 10 000 poważnych operacji w ciągu 10 lat – dr Banswal specjalizuje się w małoinwazyjnych operacjach nowotworów w HCG Manavata Cancer Centre.
Dr Kaya jest profesorem nadzwyczajnym specjalizującym się w hematologii i przeszczepach komórek macierzystych, posiadającym bogate doświadczenie w leczeniu chłoniaków.
Dr Girish Badarkhe specjalizuje się w chemioterapii chłoniaków, posiadając ponad 13-letnie doświadczenie w leczeniu nowotworów hematologicznych.
19 lat doświadczenia i ponad 50 000 operacji onkologicznych – dr Nagarkar koncentruje się na poprawie jakości życia po leczeniu.
Profesor Itir Sirinoglu Temiz koncentruje się na chłoniakach i nowotworach hematologicznych, posiadając wieloletnie doświadczenie w zarządzaniu oddziałami hematologicznymi i przeszczepianiu komórek macierzystych.